ProKidney Corp [PROK] stock is trading at $1.85, down -1.60%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PROK shares have gain 12.12% over the last week, with a monthly amount glided 7.56%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Previously, Guggenheim started tracking the stock with Buy rating on September 10, 2024, and set its price target to $6. BofA Securities downgraded its rating to a Neutral. BTIG Research initiated its recommendation with a Buy and recommended $16 as its price target on July 25, 2023. Jefferies started tracking with a Buy rating for this stock on December 21, 2022, and assigned it a price target of $15. In a note dated November 10, 2022, Morgan Stanley initiated an Equal-Weight rating and provided a target price of $13 on this stock.
ProKidney Corp [PROK] stock has fluctuated between $1.18 and $4.44 over the past year. Currently, Wall Street analysts expect the stock to reach $4.67 within the next 12 months. ProKidney Corp [NASDAQ: PROK] shares were valued at $1.85 at the most recent close of the market. An investor can expect a potential return of 152.43% based on the average PROK price forecast.
Analyzing the PROK fundamentals
Gross Profit Margin for this corporation currently stands at 0.37% with Operating Profit Margin at -34.78%, Pretax Profit Margin comes in at -30.28%, and Net Profit Margin reading is -11.31%. To continue investigating profitability, this company’s Return on Assets is posted at -0.11, Equity is 0.05 and Total Capital is -0.35. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.7833 points at the first support level, and at 1.7167 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.9333, and for the 2nd resistance point, it is at 2.0167.
Ratios To Look Out For
For context, ProKidney Corp’s Current Ratio is 17.09. Also, the Quick Ratio is 17.09, while the Cash Ratio stands at 4.29.
Transactions by insiders
Recent insider trading involved Weber Darin J., Chief Regulatory Officer, that happened on Sep 19 ’24 when 16412.0 shares were sold. Officer, DARIN J WEBER completed a deal on Sep 19 ’24 to buy 16412.0 shares. Meanwhile, Chief Regulatory Officer Weber Darin J. sold 826.0 shares on Jul 26 ’24.
